Columbia Laboratories Moves to NASDAQ National Market Under New Symbol CBRX

Columbia Laboratories Moves to NASDAQ National Market Under New Symbol CBRX 


LIVINGSTON, N.J., Feb. 13  /PRNewswire-FirstCall/ -- Columbia Laboratories 
today announced that the Company's Common Stock will begin trading from today on
the NASDAQ National Market under the symbol "CBRX." Columbia's Common Stock had
previously traded on the American Stock Exchange under the symbol "COB" through
Feb. 12, 2004.

"We are very pleased to move to NASDAQ, the premier stock market for life
sciences companies,"said Fred Wilkinson, Columbia's president and chief
executive officer.  "Our listing marks another significant milestone in the
evolution of Columbia, and NASDAQ will provide the Company with improved
liquidity as well as increased visibility to healthcare investors."

"We look forward to Columbia Laboratories joining the NASDAQ National Market,"
said Bruce Aust, Executive Vice President of The NASDAQ Stock Market. "Columbia
will be joining a large group of innovative life sciences companies within our
marketplace.  We look forward to helping Columbia achieve increased recognition
with the investment community."

Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company
dedicated to research and development of women's health care and endocrinology
products, including those intended to treat infertility, dysmenorrhea,
endometriosis and hormonal deficiencies. Columbia has introduced Striant(R)
(testosterone buccal system) for treatment of hypogonadism in men. Columbia's
products primarily utilize the company's patented Bioadhesive Delivery System
(BDS) technology. For more information, please visit
http://www.columbialabs.com/.

This press release contains statements that constitute forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Those statements include statements regarding the intent, belief or current
expectations of the company and its managementteam. Investors are cautioned
that any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual results may
differ materially from those projected in the forward-looking statements. Such
risks and uncertainties include, among other things, the successful launch and
marketing of Striant(R), the impact of competitive products and pricing; success
in obtaining acceptance and approval of new products by FDA and international
regulatory agencies; competitive economic and regulatory factors in the
pharmaceutical and health care industry, general economic conditions and other
risks and uncertainties that may be detailed, from time-to-time, in Columbia's
reports filed with the Securities and Exchange Commission. The company
undertakes no obligation to publicly update any forward-looking statements. 

DATASOURCE: Columbia Laboratories



CONTACT:  Jim Apostolakis, Vice Chairman, [phone], or David

Weinberg, Chief Financial Officer, [phone], both of Columbia

Laboratories, Inc.; Investors - Ritu Baral of The Trout Group,

[phone], ext. 25, for Columbia Laboratories



Web site:  http://www.columbialabs.com/ 

Copyright